title: Tacalcitol (1,24(OH)2D3, TV-02) inhibits phorbol ester-induced epidermal proliferation and cutaneous inflammation, and induces epidermal differentiation in mice.
abstract: In this study, we examined the cutaneous effects of tacalcitol [1,24(R)(OH)2D3] on epidermal proliferation, differentiation, and skin inflammation in vivo using hairless mice. Tacalcitol was shown to inhibit epidermal proliferation using TPA-induced ornithine decarboxylase activity and DNA synthesis as indices, and the induction of epidermal differentiation using type I transglutaminase activity as an index. Tacalcitol also displayed an antiinflammatory effect on TPA-induced inflammatory changes histopathologically. These results confirm the clinical efficacy of tacalcitol in psoriasis, and suggest that it may be efficacious in the treatment of other inflammatory skin diseases.
authors.affiliation: Teijin Institute for Bio-Medical Research, Tokyo, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Sato
authors.forename: I
authors.initials: I
authors.lastname: Sugimoto
authors.forename: T
authors.initials: T
authors.lastname: Matsunaga
authors.forename: M
authors.initials: M
authors.lastname: Tsuchimoto
authors.forename: T
authors.initials: T
authors.lastname: Ohta
authors.forename: H
authors.initials: H
authors.lastname: Uno
authors.forename: M
authors.initials: M
authors.lastname: Kiyoki
mesh_terms: D000287:Administration, Topical; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000494:pharmacology; D002118:Calcium / Q000097:blood; D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D004247:DNA / Q000096:biosynthesis; D003872:Dermatitis / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D004100:Dihydroxycholecalciferols / Q000008:administration & dosage / Q000494:pharmacology*; D004790:Enzyme Induction / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology; D000078404:Epidermal Cells; D004817:Epidermis / Q000187:drug effects* / Q000378:metabolism; D005260:Female; D051379:Mice; D008812:Mice, Hairless; D009955:Ornithine Decarboxylase / Q000096:biosynthesis; D065108:Ornithine Decarboxylase Inhibitors; D011565:Psoriasis / Q000188:drug therapy; D013755:Tetradecanoylphorbol Acetate / Q000037:antagonists & inhibitors* / Q000633:toxicity; D011503:Transglutaminases / Q000096:biosynthesis
chemical_list: D000893:Anti-Inflammatory Agents; D004100:Dihydroxycholecalciferols; D004791:Enzyme Inhibitors; D065108:Ornithine Decarboxylase Inhibitors; C023850:1 alpha,24-dihydroxyvitamin D3; D004247:DNA; D011503:Transglutaminases; D009955:Ornithine Decarboxylase; D013755:Tetradecanoylphorbol Acetate; D002118:Calcium